Home
Live Updates
Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023 : comparemela.com
Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023
START study provides real-world data for AUSTEDO with the use of a 4-week patient titration kit for adults with tardive dyskinesia , including utilization and patient satisfaction
AUSTEDO is the... | June 10, 2023
Related Keywords
United States ,
American ,
Andrew Cutler ,
Eric Hughes ,
Drug Administration ,
Teva Pharmaceuticals ,
Teva Neuroscience Inc ,
Psych Congress Elevate ,
Subcutaneous Administration Olanzapine For ,
Neuroscience Education Institute ,
Mental Health Services Administration ,
National Alliance On Mental Illness ,
Teva Pharmaceutical Industries Ltd ,
National Pregnancy Registry For Atypical Antipsychotics ,
Teva Pharmaceutical Industries ,
Executive Vice President ,
Chief Medical Officer ,
Clinical Global Impression ,
Patient Global Impression ,
Associate Clinical Professor ,
Medical University ,
Neuroscience Education ,
Sample Titration Kit ,
Poster Presentations ,
Real World Effectiveness ,
Deutetrabenazine When Initiated Using ,
Week Patient Titration Kit ,
Interim Results ,
Patient Satisfaction With ,
Patient Titration Kit ,
Population Estimate ,
Patients With Tardive Dyskinesia ,
Real World Clinical Practice ,
Across Age Groups ,
Underlying Psychiatric Conditions ,
Payer Types ,
Healthcare Professional Perspectives ,
Key Impacts ,
Tardive Dyskinesia ,
Long Acting Subcutaneous Antipsychotic ,
Local Tolerability ,
Injection Site Reactions ,
Long Term Safety ,
Patients With Schizophrenia ,
Double Blind Study ,
Placebo Controlled Trial Assessing Safety ,
Subcutaneous Administration ,
Extended Release Injectable Suspension Use ,
Adults With Schizophrenia ,
Patient Characteristics ,
Transitioning Patients ,
Long Acting Injectable Antipsychotics ,
Hypothetical Case ,
Initiating Long Acting Injectable Antipsychotics ,
Release Tablets ,
Adverse Events ,
Malignant Syndrome ,
Melanin Containing Tissues ,
Adverse Reactions ,
Prescribing Information ,
Motor Impairment ,
National Pregnancy Registry ,
Atypical Antipsychotics ,
Hepatic Impairment ,
Pharmaceutical Industries ,
Private Securities Litigation Reform Act ,
Quarterly Report ,
Annual Report ,
Term Deutetrabenazine Treatment ,
Sustained Benefits ,
Open Label Extension ,
Huntington Disease ,
Nova Science ,
From Phenomenology ,
Mental Illness ,
Mental Health Services ,
Current Prescribing ,
comparemela.com © 2020. All Rights Reserved.